The gold complex auranofin sensitizes platinum resistant epithelial ovarian cancer cells to cisplatin.

ABSTRACT: Although numerous drugs have been tested to treat ovarian cancer (OC), survival rates remain low as there has been no major improvement from platinum (Pt)-based therapy and there is a high rate of Pt resistance in these tumors. Following several rounds of chemotherapy, OC cells develop Pt-resistance by increasing DNA repair and antioxidant defense mechanisms. This study aimed to design a treatment to combat recurrent stages of OC by repurposing the anti-rheumatic gold complex auranofin (AF). We demonstrate that AF enhances the efficacy of cisplatin (CDDP) in Pt-resistant epithelial OC (EOC) cells. The drug combination enhanced mitochondrial-dependent apoptosis, PARP cleavage, DNA damage, and ROS overproduction. These results suggest the potential to combine AF with CDDP as a strategy to im

SUBMITTER: Abdalbari FH 

PROVIDER: S-EPMC11995746 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature